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Abstract Chromatin remodeling is a key epigenetic process
controlling the regulation of gene transcription. Local
changes of chromatin architecture can be achieved by
post-translational modifications of histones such as methyl-
ation, acetylation, phosphorylation, ubiquitination, sumoy-
lation, and ADP-ribosylation. These changes are dynamic
and allow for rapid repression or de-repression of specific
target genes. Chromatin remodeling enzymes are largely
involved in the control of cellular differentiation, and loss
or gain of function is often correlated with pathological
events. For these reasons, research on chromatin remodeling
enzymes is currently very active and rapidly expanding,
these enzymes representing very promising targets for the
design of novel therapeutics in different areas of medicine
including oncology and neurology. In this review, we focus
on histone methylation in the nervous system. We provide
an overview on mammalian histone methyltransferases and
demethylases and their mechanisms of action, and we dis-
cuss their roles in the development of the nervous system
and their involvement in neurodevelopmental, neurodegen-
erative, and behavioral disorders.
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Introduction
In eukaryotes, genetic information is compacted within the
nucleus into chromatin. Chromatin is composed of nucleo-
somes that are themselves formed by DNAwrapped around
histone proteins. Chromatin architecture can be rapidly
changed by post-translational modifications of residues lo-
cated on histone tails. These modifications, including meth-
ylation, acetylation, phosphorylation, ubiquitination,
sumoylation, and ADP-ribosylation, can result in a chroma-
tin structure that is locally either more condensed or more
relaxed: A condensed chromatin limits the access for tran-
scription factors to DNA and may lead to transcriptionally
inactive regions, whereas a relaxed chromatin facilitates the
access for the transcriptional machinery to DNA and is
therefore more subject to active transcription. In addition,
different histone post-translational modifications can occur
simultaneously or subsequently, providing a high degree of
complexity in chromatin configurations and thereby allow-
ing for accurate control of gene expression.
In this review, we focus on histone methylation and
demethylation. Histone methyltransferases (HMTs) are
enzymes that catalyze the addition of methyl groups to
target residues of histone tails, while histone demethylases
(HDMs) remove these methyl groups. Histone methylation
is considered to be very stable as compared with other
histone marks that are more dynamic. However, the recent
discovery of HDMs [1, 2] revealed that histone methylation
is a reversible histone mark. Although our knowledge on the
specific functional roles of histone methylation enzymes is
still limited, recent progress has highlighted their key func-
tions in gene transcription and cell cycle regulation during
development and differentiation, DNA damage, and stress
response. Furthermore, several studies indicated that histone
methylation may be critically involved in disease and aging
(reviewed in [3, 4]).
Interestingly, a lot of effort has been recently invested in
elucidating the role of histone methylation in the development
and differentiation of neural cells. The mammalian nervous
system is mainly composed of neurons and glial cells. Oligo-
dendrocytes in the central nervous system (CNS) and
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Schwann cells in the peripheral nervous system (PNS) consti-
tute the myelinating glia that ensheath neurons to provide
insulation and fast conduction of electric signals. In addition
to myelinating cells, astrocytes and microglia are two other
types of glial cells of the CNS involved in different neuronal
supporting functions and processes such as inflammation.
Sensory neurons and Schwann cells originate from neural
crest cells, while other types of neurons, oligodendrocytes,
and astrocytes derive from neural stem cells and microglia
from hematopoietic stem cells. The specific program of neural
development that starts with the specification of precursor
cells into distinct neural cell types is controlled by a complex
network of transcription factors. In addition, chromatin
remodeling enzymes are coordinating the activity of key
transcription factors involved in neural development. Indeed,
we and others have shown the critical involvement of histone
deacetylases (HDACs) 1 and 2 in the development of myeli-
nating cells [5, 6]. Another good example is the enhancer of
Zeste homolog 2 (EZH2) HMT that is required to maintain a
proper balance between neural stem cell self-renewal and
differentiation into neurons [7] and that also plays a critical
role in the differentiation of neural stem cells into oligoden-
drocytes [8]. Altogether, these findings have emphasized the
importance of chromatin remodeling enzymes in the differen-
tiation and maturation of the nervous system.
Beyond a critical involvement in development, chromatin
remodeling is very likely to be also implicated in pathologies
of the nervous system: Accumulation of specific histone
marks correlates with several neurological disorders, and re-
cent studies suggest that histone methylation enzymes are
essential to the proper function of the nervous system [9, 10].
In this review, we describe the different known mamma-
lian members of histone methyltransferase and demethylase
families, their mechanism of action, their critical functions
in the development of the nervous system, and their involve-
ment in neurodevelopmental, neurodegenerative, and be-
havioral disorders.
HMTs and HDMs
HMTs catalyze the transfer of methyl groups from S-adeno-
sylmethionine (SAM) to histones [11]. Three families of
HMTs have been described: the SET (Su(var)3–9, enhancer
of Zeste, trithorax)-domain-containing proteins [12] and
DOT1-like proteins [13] catalyzing the methylation of ly-
sine residues, and the protein arginine N-methyltransferases
(PRMTs) that methylate arginine residues [14] (Fig. 1).
The removal of methyl groups from lysine residues on
histones is catalyzed by HDMs. Two families of lysine
HDMs, the amine oxidases [1] and the Jumonji C (JmjC)
domain-containing proteins, have been identified (Fig. 1).
However, the existence of specific arginine HDMs is not
clear: The JmjC-domain-containing protein JMJD6 has been
shown to demethylate arginines [15], but this enzyme is also
a lysyl hydroxylase [16]. Another way for cells to get rid of
methylated arginines is to use deiminases that convert argi-
nines into citrullines [17]; however, these enzymes are not
able to demethylate arginines.
Structure and Catalytic Mechanisms of Histone Methylation
Enzymes
HMTs
SET-domain-containing HMTs possess, in addition to their
SET domain (containing the catalytic core), a pre-SET do-
main and a post-SET domain that are involved in the meth-
yltransferase activity and specificity of the enzyme. In order
to methylate histone tails, the SET domain of HMTs first
recognizes lysines and SAM molecules, which are brought
in close proximity, then catalyzes the deprotonation of the ε-
amino group of the lysine residue by a nearby tyrosine to
allow the transfer of the methyl group from the SAM mol-
ecule to the lysine residue [18].
In contrast to SET-domain-containing enzymes that target
lysine residues on histone tails, Dot1 HMT was shown in
budding yeast to only methylate lysine residues in the glob-
ular histone core [19]. Dot1-like HMT (DOT1L) homologs
have been identified in mammals [13]. A structural study of
the catalytic domain of human DOT1L reveals common
features with other methyltransferases that do not methylate
lysine residues; however, this study identifies a potential
binding channel for lysine residues [20]. Further structural
studies are still needed to understand the precise catalytic
mechanism of this enzyme.
The catalytic domain of PRMTs, consisting of a SAM
binding domain and a substrate binding domain, recognizes
arginine residues brought in close proximity to SAM
Fig. 1 Histone methyltransferase and demethylase families. Histone
methylation is catalyzed by histone methyltransferases that belong to
three identified families, while the removal of methyl groups on
histone residues is catalyzed by histone demethylases that include











molecules. Arginine residues are then deprotonated by a
nearby glutamate to allow the transfer of the methyl group
from the SAM molecule to the arginine residue [21].
For complete review about HMT structures and catalytic
mechanisms, see also Wood and Shilatifard [22].
HDMs
Amine oxidases such as LSD1 contain a C-terminal amine
oxidase-like domain that includes two subdomains: a
FAD-binding subdomain and a substrate-binding subdo-
main [23]. A large cavity formed by these two subdo-
mains constitutes the catalytic core of the enzyme. LSD1
activity depends on the cofactor FAD. LSD1 catalyzes the
transfer of two hydrogens from a methylated lysine to a
FAD that is then reduced into FADH2; this reaction even-
tually results into an unmethylated lysine and a formalde-
hyde byproduct [1].
JmjC-domain-containing demethylases catalyze hydrox-
ylation reactions. This second family of HDMs introduces a
hydroxyl group into a methyl group on a lysine residue
using Fe(II) and α-ketoglutarate as cofactors to generate
succinate and an unstable carbinol amine intermediate that
leads to the formation of an unmethylated lysine and a
formaldehyde byproduct [24, 25].
Target Residues and Methylation Outcome
Histone methylation can occur on the three basic residues
lysine (K), arginine (R), and histidine; however, histidine
methylation is rarely observed. Lysines can be mono- (me1),
di- (me2), or trimethylated (me3); arginines can be mono- or
dimethylated, whereas only monomethylation of histidine
has been described.
Histone methylation sites are mainly located on histones
H3 and H4; however, methylation can also occur on histones
H1, H2A, and H2B. The most described methylation sites are
listed in Tables 1 and 2. The effect of histone methylation on
gene expression activity depends on the location of the meth-
ylated residue and can also depend on the degree of methyl-
ation and the HMT (whether the enzyme catalyzes symmetric
or asymmetric methylation): H3K9, H3K27, H4K20, and
H3R8 methylations are described as marks of transcriptional
repression (reviewed in [26], [27], and [28]) H3K4 [29, 30],
H3K36 (reviewed in [31]), H3K79 (reviewed in [32]),
H3R17, and H3R26 (reviewed in [33]) methylations are most-
ly (but not always, e.g., [29]) associated with active transcrip-
tion, whereas methylation of H3R2 and H4R3 (reviewed in
[33]) can either lead to transcriptional activation or re-
pression, depending on the degree of methylation and/or
the type of methyltransferase. The most common effects
of currently described HMTs and HDMs are summa-
rized in Tables 1 and 2.
Enzyme Recruitment to Histone Target Residues
Several studies have shown that specific DNA sequences,
long non-coding RNAs (lncRNAs), small non-coding
RNAs, and DNA methylation could direct histone methyl-
ation enzymes to their target sites.
In Drosophila melanogaster, specific DNA sequences
including the polycomb group (PcG) response elements
(PREs) and the trithorax group response elements are able
to recruit histone methylation enzymes such as, respectively,
PcG proteins and the H3K4 methyltransferase Trx [34, 35].
In humans, a D11.12 (region between HOXD11 and
HOXD12) genomic element with similar recruitment abili-
ties of PcG proteins as compared with Drosophila PREs has
been recently identified, suggesting that the recruitment of
histone methylation enzymes by specific DNA sequences
may as well occur in mammals [36]. In addition, the JmjC
protein JARID2 [37] and polycomb-like 2 [38] have been
shown to be able to recruit PRC2, a PcG complex having
H3K27 trimethylation activity [39].
Several studies have also reported or suggested the ability
of lncRNAs to target HMTs and HDMs to regulatory regions
of specific genes. Indeed, Hawkins and Morris showed that
the suppression of the lncRNA antisense to Oct4-pseudogene
5 in human cells resulted in increased transcription of Oct4
gene and Oct4 pseudogenes 4 and 5, correlating with loss of
the HMT EZH2 at the Oct4 promoter and therefore indicating
the requirement of this lncRNA to target EZH2 to Oct4 gene
[40]. In addition, the lncRNA HOTAIR has been shown to
bind and recruit PRC2 and the demethylase LSD1 [41]. An-
other study reports the recruitment of the protein complex
containing the H3K4 methyltransferase mixed lineage leuke-
mia (MLL) and WD repeat-containing protein 5 (WDR5) by
the lncRNA HOTTIP [42].
Small non-coding RNAs including microRNAs, small-
interfering RNAs and Piwi-interacting RNAs have important
functions in transposon silencing, formation of pericentro-
meric heterochromatin [43], and X-chromosome inactivation
[44]. They often play the role of inducers of these mechanisms
by recruiting HMTs (reviewed in [45]).
Finally, there is often interplay between DNA methylation
and histone methylation. The study of Bartke et al. [46] shows
that, in some cases, the recruitment of HMTs is enhanced by
the presence of DNA methylation, and in other cases, DNA
methylation counteracts the recruitment of HMTs.
For a general review addressing this question, see also,
Greer and Shi [3].
Complex Formation and Histone Modification Crosstalk
Changes in chromatin structure often result from a specific
combination of post-translational modifications of histones. In











Table 1 Mammalian histone lysine methyltransferases and demethylases and prevalent transcriptional outcome of methylation (reported enzymes
and their alternative names in brackets are sorted depending on the target residue and the degree of methylation)
Histone and
residue
Methyltransferase Prevalent methylation outcome Demethylase
H3K4 me1 SETD1A/B (SET1A/B, KMT2F) Transcriptional activation LSD1/2 (KDM1A/B)
ASH1L (KMT2H) KDM5B (JARID1B, PLU1)
MLL1 (KMT2A, TRX1, HRX, ALL1) Transcriptional activation NO66 (MAPJD)
MLL2 (MLL4, KMT2B, KMT2D, ALR) Transcriptional activation
MLL3 (KMT2C) Transcriptional activation
SETD7 (SET7/9, KMT7) Transcriptional activation
me2 SETD1A/B (SET1A/B, KMT2F) Transcriptional activation LSD1/2 (KDM1A/B)
MLL1 (KMT2A, TRX1, HRX, ALL1) Transcriptional activation KDM5A (RBP2, RBBP2)
MLL2 (MLL4, KMT2B, KMT2D, ALR) Transcriptional activation KDM5B/D
MLL3 (KMT2C) Transcriptional activation KDM5C (JARID1C, SMCX)
SMYD3 Transcriptional activation NO66 (MAPJD)
me3 SETD1A/B (SET1A/B, KMT2F) Transcriptional activation KDM2B
ASH1L (KMT2H) KDM5A (RBP2, RBBP2)
MLL1 (KMT2A, TRX1, HRX, ALL1) Transcriptional activation KDM5B/D
MLL2 (MLL4, KMT2B, KMT2D, ALR) Transcriptional activation KDM5C (JARID1C, SMCX)
MLL3 (KMT2C) Transcriptional activation NO66 (MAPJD)
SMYD3 Transcriptional activation
PRDM9 (MEISETZ)
H3K9 me1 SETDB1 (ESET, KMT1E) Transcriptional repression KDM3A/B (JMJD1A/B, JHDM2A/B)
G9a (EHMT2, KMT1C) Heterochromatin formation/silencing PHF8
GLP (EHMT1, KMT1D) KDM7 (JHDM1D)
PRDM2 (KMT8)
me2 SUV39H1/2 (KMT1A/B) KDM3A/B (JMJD1A/B, JHDM2A/B)
SETDB1 (ESET, KMT1E) KDM3A/B (JMJD1A/B, JHDM2A/B)
G9a (EHMT2, KMT1C) Heterochromatin formation/silencing PHF8
GLP (EHMT1, KMT1D) Heterochromatin formation/silencing LSD1 (KDM1A)
PRDM2 (KMT8) KDM7 (JHDM1D)
me3 SUV39H1/2 (KMT1A/B) Heterochromatin formation/silencing KDM3B (JMJD1B, JHDM2B)
SETDB1 (ESET, KMT1E) KDM4A-D (JMJD2A-D, JHDM3A-D)
PRDM2 (KMT8)
H3K27 me1 KMD7 (JHDM1D)
me2 EZH1/2 Transcriptional repression KDM6A/B (UTX/JMJD3)
KDM7 (JHDM1D)
me3 EZH1/2 Transcriptional repression KDM6A/B (UTX/JMJD3)
H3K36 me1 SETD2 (KMT3A) Transcriptional activation KDM2A/B (JHDM1A/B, FBXL11/10)
NSD1-3
me2 NSD1-3 KDM2A/B (JHDM1A/B, FBXL11/10)
SMYD2 NO66 (MAPJD)
SETD2 (KMT3A) Transcriptional activation KDM4A-C (JMJD2A-C, JHDM3A-C)
ASH1L
me3 SETD2 (KMT3A) Transcriptional activation NO66 (MAPJD)
KDM4A-C (JMJD2A-C, JHDM3A-C)
H3K79 me1 DOT1L (KMT4) Transcriptional activation
me2 DOT1L (KMT4) Transcriptional activation
me3 DOT1L (KMT4) Transcriptional activation














assembly of protein complexes containing several histone-
modifying enzymes. HMTs and/or HDMs are frequently
found in these protein complexes. Because of the particular
role of histone acetylation and deacetylation in chromatin
dynamics of the nervous system, we will focus on the protein
complexes containing HMTs or HDMs and histone acetyl-
transferases (HATs) or HDACs. The PRC2 complex contain-
ing EZH2 has also a key role in the development of nerve cells
and will be therefore described in this section.
H3K4 HMT Complexes
Most MLL HMTs targeting H3K4 act within multipro-
tein complexes that contain a three-subunit core com-
posed of WDR5, RbBP5, and ASH2L, necessary for the
methyltransferase activity [47]. The MLL1 complex, a
key regulator of Hox genes during development, con-
tains also the H4K16 HATs MOF/KAT8 [48] or MOZ
[49] and other cofactors that act together to regulate
transcription initiation and elongation [50–53]. The ac-
tivity of this MLL complex is stimulated by the acety-
lation of H3K9 or H3K14 [50], demonstrating the
critical role of crosstalk between different histone mod-
ifications for the regulation of target genes.
H3K9 HMT Complexes
In contrast to MLL HMTs, SETDB1 HMT targets H3K9
residue to induce gene silencing or heterochromatin forma-
tion. SETDB1 can robustly methylate unmodified histone
H3, whereas acetylation of H3K9 or H3K14 strongly inhib-
its SETDB1 activity. For this reason, SETDB1 HMT needs
to act in concert with a deacetylase complex. Consistent
with this, SETDB1 interacts with the co-repressor KAP-1
that serves as a scaffold for KRAB zinc-finger proteins that
target the protein complex to specific promoters, for the
NuRD complex (containing HDAC1 and HDAC2) required
for deacetylation of histone H3, and for HP1 (heterochro-
matin protein 1) that allows formation of heterochromatin
[54, 55].
Similarly to SETDB1, Suv39H1 HMT recruits HP1 by
methylating H3K9 and is involved in heterochromatin for-
mation and in transcriptional repression. Suv39H1, such as
SETDB1, functionally interacts with HDAC1 or HDAC1/2
[56, 57].
G9a HMT also targets H3K9. G9a plays a critical role in
transcriptional repression, and studies in mice revealed that
this HMT is essential for early embryonic development [58].
G9a recruits HP1 and has been shown to associate with
transcriptional repressors such as HDAC1/2 and DNA
methyltransferases [59, 60].
H3K27 HMT Complexes
The polycomb repressive complex PRC2 induces gene si-
lencing by the di- and trimethylation of H3K27 catalyzed by
the HMTs EZH2 or EZH1 ([39, 61] and reviewed in Mar-
gueron and Reinberg [62]). PRC2 can also methylate H3K9
and H1K26, which leads to the recruitment of the PRC1
complex that represses genes through monoubiquitylation of




Histone and residue Methyltransferase Prevalent methylation outcome
H3R2 me1 PRMT4 (CARM1) Transcriptional activation
PRMT6 Transcriptional repression
PRMT5/7
me2 PRMT4 (CARM1) Transcriptional activation
PRMT6 Transcriptional repression
PRMT5/7
H3R8 me1 PRMT5 (SKB1) Transcriptional repression
me2 PRMT5 (SKB1) Transcriptional repression
H3R17 me1 PRMT4 (CARM1) Transcriptional activation
me2 PRMT4 (CARM1) Transcriptional activation
H3R26 me1 PRMT4 (CARM1)
me2 PRMT4 (CARM1)
H4R3 me1 PRMT1 (HMT2) Transcriptional activation
PRMT5 (SKB1) Transcriptional repression
PRMT6/7
me2 PRMT1 (HMT2)













histone H2A [63]. PRC2 comprises four core components
that are required for its activity: EZH1/2, embryonic ecto-
derm development protein (EED), RbAp46/48, and SUZ12
(suppressor of Zeste 12 homolog). EZH2 and EZH1 are
both able to methylate H3K27; however, EZH1 has lower
methyltransferase activity than EZH2 [64]. EED and
RbAp46/48 are both WD40 repeat containing proteins.
EED allows recognition of the H3 substrate by PRC2 [65]
and the propagation of H3K27 methylation [66] while
RbAp46/48, which can bind histone H3, SUZ12, and his-
tone H4, may be involved in substrate specificity [39].
SUZ12 contains a zinc-finger domain that is important for
the recruitment of PRC2 to its target genes [67, 68]. Beyond
these four core components, other proteins are found in
PRC2 complexes: the zinc-finger protein AEBP2, the
polycomb-like protein PCL1 (also known as PHF1), and
the Jumonji protein JARID2. These three proteins are in-
volved in the regulation and enhancement of PRC2 activity
and in the recruitment of the complex [69–71]. PRC2 is
required for X inactivation and silencing of Hox gene ex-
pression during embryonic development and has key func-
tions in stem cell self-renewal, but also in lineage
commitment and maintenance of cellular identity [reviewed
in Margueron and Reinberg and Walker et al. 62, 72].
HDM Complexes
The first described histone demethylase LSD1 that can
target methylated H3K4 or H3K9 is involved in diverse
molecular interactions. LSD1 has been initially found to
be part of the repressive CoREST complex, which also
consists of HDAC1/2, BHC80, and BRAF35 [1, 73]. Addi-
tionally, other studies revealed that the CoREST complex is
part of another transcriptional corepressor complex, CtBP,
which also contains G9a and GLP HMTs and other cofac-
tors [74]. Finally, LSD1 has also been identified as a com-
ponent of the NuRD complex, where it also acts as
transcriptional repressor by demethylating H3K4. The
NuRD complex exhibits an ATP-dependent chromatin
remodeling activity, together with the presence of HDAC1/
2, Mi-2 and histone-binding proteins [75].
NCoR protein, which is known to act within a multimeric
protein complex involved in development and neural differen-
tiation, has also been shown to associate with HDMs. Indeed, a
repressive complex containing NCoR protein, REST, and
HDAC1/2 was found to be associated to G9a HMT and
KDM5C, a demethylase of H3K4me2 and H3K4me3 [76].
Another HDM, KDM4A, that demethylates H3K36, seems to
be required in the NCoR complex for selective repression of
Ascl2 gene, a basic helix–loop–helix transcription factor essen-
tial for proper placental development [77].
Finally, the highly conserved Sin3-HDAC complex,
which regulates many genes and has fundamental roles in
development, has been shown to associate with the H3K4
HDM KDM5A. This Sin3 complex is constituted of
HDAC1/2, Sin3A or Sin3B, RbAp46/48, and SAP18/30,
together with other factors such as MRG15, which is in-
volved in the recruitment of KDM5A [78].
As mentioned previously, we only referred to literature
that described HMTs or HDMs in complex with HATs or
HDACs and to the PRC2 complex. Other important inter-
actions, such as HDMs with nuclear hormone receptors [79,
80], have also been described but are not discussed here.
Histone Methylation in the Nervous System
We and others have shown that several members of the
HDAC family are crucial for the development of myelinat-
ing cells (reviewed in Jacob et al. [6]). Because HMTs and
HDMs are often found in multiprotein complexes where
HDACs are present and play an essential role in the activity
of these complexes, it is very likely that histone methylation
enzymes and HDACs have coordinated functions in the
development of the nervous system. In this section, we will
first discuss the functions of histone methylation in the
development and differentiation processes of nerve cells,
including neurons, oligodendrocytes, and Schwann cells,
the myelinating cells of the CNS and PNS, respectively,
and astrocytes and microglia, two other important types of
glial cells in the CNS. As mentioned before, sensory neu-
rons and Schwann cells originate from neural crest cells
while other neurons, oligodendrocytes, and astrocytes orig-
inate from neural stem cells and microglia are generated
from hematopoietic stem cells. Beyond a key involvement
in development, histone methylation is very likely to play
important roles in diseases of the nervous system. The
second part of this section will be focused on suggested
implications of histone methylation in neurodevelopmental
and neurodegenerative diseases and in behavioral disorders.
Histone Methylation in the Development and Differentiation
of the Nervous System
Neurons
Much more information is available regarding the role of
histone methylation in neurogenesis, as compared with the
differentiation process of other cells of the nervous system.
The methylation status of H3K27 is a key determinant of
cell fate during neural lineage progression from neural stem
cells [8]. Consistent with this, JMJD3, an H3K27me3 deme-
thylase, induces expression of neuronal genes such as Dlx5,
Gad1/2, and Dcx [81]. Additionally, studies on embryonic
stem cells also demonstrated that JMJD3 is required for











TGFbeta-responsive genes in neurons [83]. However, meth-
ylation of H3K27 by EZH2 in neural stem cells is required
to maintain a proper balance between self-renewal of neural
stem cells and differentiation into neurons and to prevent
massive neurogenesis and depletion of the neural stem
cell pool that would eventually result in a decreased
number of neurons [7]. Moreover, the nuclear co-
receptor SMRT, repressing the expression of JMJD3, is
critical for forebrain development and maintenance of
the neural stem cell state [81].
Histone methylation at H3K4 has also been shown to
play a role in neurogenesis. Indeed, the H3K4 HMT MLL1
promotes neurogenesis in the subventricular zone of the
mouse postnatal brain by promoting the expression of
Dlx2, a homeodomain-containing transcription factor criti-
cal for olfactory bulb interneuron development and migra-
tion [84]. Another study in mice revealed that a complex
containing MLL2, MLL3, and PTIP is necessary to maintain
H3K4 methylation in the neural tube during embryonic
development [85]. Consistent with this, the H3K4 HDM
KDM5C that acts as a transcriptional repressor has been
shown to associate with the REST complex, which represses
neuronal genes in non-neuronal tissues. The complex
KDM5C and REST associates at a subset of REST-target
genes and depletion of KDM5C induces de-repression of
several of these target genes [76], suggesting that KDM5C
contributes to REST-mediated neuronal gene regulation. In
addition to maintaining silencing of neuronal genes in non-
neuronal cells, the REST complex is also involved in
the differentiation into neurons: The activation of most
neuronal genes (designed as class 1) in post-mitotic
neurons is only dependent on the release of the REST
repressor complex from these genes at the RE1 binding
motif, while a smaller group of neuronal genes
(designed as class 2) including Bdnf remains initially
expressed at low levels upon differentiation into neurons
even after the release of the REST complex. This is due
to the presence of the CoREST and MeCP2 repressor
complex on these genes, which is eventually released
later by membrane depolarization [86]. The study of
Abrajano et al. comparing the different profiles of
REST and CoREST target genes in distinct subtypes
of neurons shows that the differential presence of these
two repressor complexes allows the induction and main-
tenance of neuronal subtype identity [87].
The status of H3K9 methylation seems also to be in-
volved in neuronal differentiation and in particular in neurite
outgrowth. Indeed, Sen and Snyder showed that BDNF, by
activating neuronal nitric oxide synthase, induces the deg-
radation of the H3K9 HMT SUV39H1, resulting in the
decrease of H3K9 methylation and subsequent increase of
H3K9 acetylation. This facilitates CREB binding to DNA
and enhances CREB-regulated genes and neurite outgrowth
[88]. Consistently, the H3K9/H4K20 HDM PHF8 has been
shown to be essential in neurons to promote cytoskeleton
dynamics resulting in neurite outgrowth [89]. H3K9 meth-
ylation needs to be decreased for neurite outgrowth; how-
ever, this histone mark seems necessary for early
neurogenesis. Indeed, ablation of the H3K9 HMT SETDB1
in neural stem cells leads to enhanced formation of astro-
cytes and severe decrease of early born neurons [90]. The
authors of this study show that SETDB1 represses the
expression of astrocytic genes and thereby prevents preco-
cious differentiation of neural stem cells into the astrocytic
lineage. This mechanism could be required for upregulation
of neuronal genes and early neurogenesis.
Interestingly, a recent expression study comparing human
cortical neurons to neural progenitor cells reports the tran-
scriptional regulation of many chromatin modifiers during
human neurodevelopment and identifies the arginine HMT
PRMT8 and the lysine HMT EZH1 as new markers of post-
mitotic neurons [91].
Oligodendrocytes
Interesting findings on the implication of histone methyla-
tion in the development of myelinating cells have just
started to emerge.
Histone methylation has been shown to play a critical
role in the specification of the oligodendrocyte lineage from
neural stem cells. Indeed, the HMT EZH2 is needed for
proper in vitro specification of mouse neural stem cells into
oligodendrocytes. While EZH2 is highly expressed in pro-
liferating neural stem cells, its expression is decreased upon
differentiation into neurons and abolished during differenti-
ation into astrocytes. However, EZH2 expression remains
high in oligodendrocytes [8]. A comparative ChIP-Seq anal-
ysis of EZH2 target genes in neural stem cells and in
premyelinating oligodendrocytes (pOLs) reports the pres-
ence of EZH2 at oligodendrocyte, neuronal, and astrocytic
lineage-specific genes in neural stem cells, whereas, in
pOLs, EZH2 is not anymore present on the oligodendrocyte
lineage-specific genes but is still found on astrocytic and
neuronal lineage-specific genes [92].
Histone methylation may also play a role in oligodendro-
cyte development at later stages, from oligodendrocyte pro-
genitor cells into mature myelinating cells. Interestingly, an
increase of the repressive histone mark H3K9me3 and
HP1α, a marker of stable chromatin compaction, has been
observed in mature oligodendrocytes of the rat corpus cal-
losum [93]. This suggests a possible role of histone meth-
ylation in maintaining oligodendrocytes in a differentiated
myelinating stage, but the underlying mechanisms and
enzymes involved in this process remain unknown.
Finally, the REST and CoREST complexes that repress











neuronal cells are also necessary for the differentiation pro-
cess of oligodendrocytes. Similar to their study in neurons,
Abrajano et al. have compared the profiles of REST and
CoREST target genes during the different stages of oligo-
dendrocyte development [94].
Schwann Cells
There was no information available about the potential role
of histone methylation in Schwann cell differentiation until
Heinen et al. recently showed that EZH2 is required for
Schwann cell maturation [95]. Indeed, suppression of
EZH2 in Schwann cell cultures and dorsal root ganglia
cultures leads to the downregulation of myelin genes (P0,
PMP22, and MAL) and reduction of process extension.
EZH2 binds to and represses the promoter of the cyclin-
dependent kinase inhibitor p57kip2 and thereby downregu-
lates the expression of transcriptional repressors of myelin
genes such as Hes5 [95]. The same authors of this study
previously demonstrated that p57kip2 is a negative regulator
of Schwann cell differentiation and in vitro myelination
[96]. Altogether, these results suggest that EZH2 activity
within the PRC2 complex is necessary to initiate suppres-
sion of differentiation inhibitors in Schwann cells, therefore
allowing Schwann cell differentiation and maturation.
Astrocytes
As with myelinating cells, little is known about the role of
histone methylation in astrocyte development and differentia-
tion.We previouslymentioned that EZH2 expression in neural
stem cells is downregulated upon differentiation into neurons
and abolished during differentiation into astrocytes [8]. Inter-
estingly, important changes in H3 methylation have been
observed on the promoter of the Gfap gene, a marker of the
astrocytic lineage. Indeed, fibroblast growth factor 2 (FGF2)
has been shown to induce H3K4 methylation and to reduce
H3K9 methylation on the Gfap promoter. This facilitates the
access of the STAT/CBP complex to the Gfap promoter and
allows ciliary neurotrophic factor-mediated astrocyte differen-
tiation [97]. However, the underlying mechanism of HMTs
and/or HDMs recruitment by FGF2 has not been elucidated
yet. Consistently and as mentioned earlier, the H3K9 HMT
SETDB1 represses astrocytic genes in neural stem cells and
ablation of SETDB1 results in increased astrogenesis [90].
Microglia
Unfortunately, there is currently no evidence concerning the
role of histone methylation in microglia development or
differentiation. However, some studies reported an implica-
tion of histone methylation enzymes in the inflammatory
response and the establishment of HIV-1 latency in
microglia. Indeed, microglial cells are the principal targets
of HIV-1 in the nervous system and constitute a latent
reservoir for the virus [98]. Some studies demonstrated a
recruitment of a chromatin-modifying complex containing
HDAC1/2 and the H3K9 HMT SUV39H1 by the co-
repressor COUP-TF interacting protein 2 (CTIP2) at the
viral promoter of HIV-1 in microglia [99]. The authors also
demonstrated that this complex associates with the promoter
of the cyclin-dependent kinase inhibitor p21, whose expres-
sion is affected in HIV-1 infected microglia [100]. Addition-
ally, they showed that the HDM LSD1 can also interact with
CTIP2 to silence HIV-1 promoter [101]. Altogether, these
repressive complexes may thus participate in the mainte-
nance of HIV-1 latency in microglia.
In a different context, the CoREST repressor complex
containing G9a HMT and LSD1 HDM is recruited by the
orphean nuclear receptor Nurr1 to repress the promoters of
inflammatory target genes [102]. Since the Nurr1/CoREST
complex exerts a regulatory role on inflammatory gene
expression, it is likely that histone methylation could play
a potential role in the control of inflammation in microglial
cells.
Reported functions of histone methylation in the devel-
opment and differentiation processes of neurons, myelinat-
ing cells, and astrocytes are summarized in Table 3 and
illustrated in Figs. 2, 3, and 4.
Nervous System Disorders Related to Histone Methylation
As mentioned earlier, accumulations of several histone mod-
ifications including methylation have been shown to corre-
late with neurological disorders. These modifications vary
from one disorder to another, and it is not always clear
whether they are a cause or a consequence of the disease.
Understanding the mechanisms underlying these histone
modifications observed in pathological conditions is of ut-
most importance for the design of novel therapeutic treat-
ments. The following section focuses on recent findings
related to histone methylation processes that have been
correlated to neurodevelopmental and neurodegenerative
diseases and behavioral disorders (summarized in Table 4).
Neurodevelopmental Diseases
Mutations of H3K4 KDM5C [103–107] and of H3K9/
H4K20 PHF8 [108–110] HDMs have been linked to mental
retardation (for KDM5C and PHF8) and facial deformity
(for PHF8) in humans. The genes encoding these two
HDMs are located on the X chromosome, where genes
affecting cognitive functions seem to be more represented
when compared with autosomes. Interestingly, these neuro-
logic phenotypes are consistent with the expression patterns











expressed and seems to have important functions in brain
regions involved in cognition such as the hippocampus
[125]. Some studies performed in zebrafish, and primary
mammalian neurons showed that these phenotypes could be
due to disrupted brain development. Indeed, neuronal sur-
vival and dendritic development are affected by mutation of
KDM5C [126]. Concerning PHF8, a role for this HDM in
zebrafish neuronal cell survival and craniofacial develop-
ment has been identified [127], providing new insights into
the related human pathology.
The Kleefstra syndrome, caused by either deleterious
mutations or haploinsufficiency of the H3K9 HMT EHMT1
[111], includes mental retardation and other developmental
defects. Interestingly, heterozygous Ehmt1 knockout mice
Table 3 Functions of histone methylation enzymes in the development and differentiation of neural cells
Cell type Target
residue
Enzyme Modification Observation Suggested role References
Neurons H3K27 KDM6B
(JMJD3)
Demethylation Neuronal genes induced
when JMJD3 is overexpressed
in neural stem cells
Promotes differentiation of neural
stem cells into neurons
[81–83]
EZH2 Methylation Upregulation of genes involved
in neurogenesis in Ezh2-null
mouse cortex
Maintenance of appropriate balance
between neural stem cell
self-renewal
and differentiation into neurons
[7]
EZH1 Methylation High expression in
post-mitotic neurons
[91]
H3K4 MLL1 Methylation Neurogenesis impaired in the
absence of MLL1 in mouse
subventricular zone (SVZ)
Induces postnatal neurogenesis in the





Demethylation KDM5C and REST are released
from RE1 binding sites upon
differentiation into neurons
Cell identity establishment by
REST-mediated silencing of neuro-
nal genes in non-neuronal cells and
de-repression of neuronal genes by
relase of REST for differentiation
into neurons
[76]
H3K9 SETDB1 methylation Early neurogenesis severely
impaired and increased
astrogenesis in the absence of
SETDB1
Represses astrocytic genes to prevent
precocious differentiation in




SUV39H1 Methylation Downregulation of SUV39H1
induced by BDNF enhances
CREB-related genes
Neurite outgrowth promoted by
downregulation of SUV39H1 and





PHF8 Demethylation Activation of genes involved in
cytoskeleton dynamics
Neurite outgrowth [89]
H4R3 PRMT8 Methylation Hig hexpression in post-mitotic
neurons
[91]




it represses astrocytic and
neuronal lineages specific
genes
Cell fate choice towards
oligodendrocytic lineage upon
induction of neural stem cell











Schwann cells H3K27 EZH2 Methylation Decrease of myelin gene
expression and process
extension in Schwann cells
upon downregulation of EZH2
Promotes Schwann cell maturation by
repressing p57kip2, what
downregulates inhibitors of




Methylation Increased H3K4 methylation on
the GFAP promoter
Mediates FGF2-dependent astrocyte






















develop autistic-like behavior that resembles the human
pathology [128]. EHMT1 is part of a multiprotein complex
that also includes the H3K9 HMT G9a as well as other
methyltransferases [129]. Conditional mutagenesis of
Ehmt1 and G9a in postnatal mouse brain revealed the im-
portance of this complex for the silencing of non-neuronal
genes and progenitor genes in mature neurons. Furthermore,
absence of the EHMT1/G9a complex has detrimental effects
on cognition and other higher brain functions [130].
Neurodegenerative Diseases
Aberrant histone modifications related to methylation have
been detected in Friedreich ataxia, Huntington’s disease,
and Alzheimer disease (AD), three neurodegenerative dis-
eases of the CNS. Friedreich ataxia is an autosomal neuro-
degenerative disorder caused by abnormally high copy
numbers of GAA repeats in the frataxin gene [131]. Inter-
estingly, analyses of human brain tissues revealed increased
Fig. 2 Known functions of histone methyltransferases and demethylases in the specification and differentiation of neurons, oligodendrocytes, and
astrocytes
Fig. 3 Functions of REST and CoREST complexes in the specification
and differentiation of neurons, oligodendrocytes, and astrocytes. Note
that other proteins such as BHC80 and BRAF35 also belong to the
CoREST complex, and the HMT G9a can also be associated with











levels of H3K9 methylation together with decreased histone
acetylation at the frataxin gene, resulting in transcriptional
repression of this gene [9].
Similarly, high levels of methylated H3K9 and its
corresponding SETDB1 HMT have been detected in post-
mortem human striatal tissues of patients suffering from
Huntington’s disease. Huntington’s disease is caused by a
mutation in the huntingtin gene that creates an expansion of
a CAG trinucleotide repeat encoding poly-glutamine [112].
Mutated huntingtin interferes with the normal function of
neuroprotective factors such as Sp1 and CREB-binding
protein, which renders mutated huntingtin neurotoxic
[132–134].
Increased levels of H3K9 trimethylation have also been
detected in the postmortem brain of a patient suffering from
AD, as compared with the levels of H3K9me3 detected in
the brain of his twin brother that did not suffer from AD
[113]. AD is linked to age-related changes in the metabolism
of beta-amyloid (Aβ) precursor protein and tau protein,
resulting in aggregates of Aβ fibrils and neurofibrillary
tangles that may impact neuronal integrity (reviewed in
Huang et al. [135]). The increased H3K9me3 in human
brain described above seems rather anecdotic; however,
studies in a transgenic mouse model of AD also showed
an increase of histone H3 methylation in the presence of Aβ
in the prefrontal cortex of these mice [114].
Finally, we can mention the progressive decline of
histone methylation marks in oligodendrocytes during
aging, which is associated with increased histone acet-
ylation and re-expression of inhibitors of myelin pro-
teins [115]. This loss of histone methylation could play
a role in the decreased efficiency of remyelination
during aging [116].
Behavioral Disorders
Different histone methylation marks have been associated
with behavioral disorders. This topic has been recently
extensively reviewed elsewhere [10]. In this section, we
have therefore briefly pointed out the most important find-
ings. H3K27, H3K9, and H3K4 methylation marks have
been shown to play a role in the development of mood
disorders and depression-like behaviors in mice. BDNF is
involved in the adaptation of the hippocampus to stress
[136], and histone methylation could be part of the regula-
tory mechanisms mediating its expression. Interestingly,
chronic defeat stress induces H3K27 methylation at the Bdnf
gene in mouse hippocampus, leading to transcriptional re-
pression [117]. Consistent with these results, mice exposed
to environmental enrichment demonstrated a strong increase
in BDNF mRNA expression in hippocampus, associated
with decreased H3K27 and H3K9 methylation together with
increased H3K4 methylation [118]. Additionally, studies
about global histone methylation in rat dentate gyrus during
acute and chronic stress revealed important changes in
H3K9, H3K27, and H3K4 methylation levels, giving more
evidence to the mechanisms involved in the hippocampal
response to stress [137]. Other studies about the effect of
social defeat model on gene transcription in the mouse
nucleus accumbens, a brain reward region implicated in
depression, revealed important histone modification
changes. Levels of repressive H3K9me2 and H3K27me2
were increased at several gene promoters in stress-
susceptible animals, including at the promoter of the
H3K9 HDM KDM3A. Interestingly, mice resilient to the
stress model or treated with conventional antidepressants
did not show changes in histone H3 methylation, providing
new insights into the molecular mechanisms of depression-
like behaviors and antidepressant activity [119]. Finally,
overexpression of the H3K9 HMT SETDB1 in adult fore-
brain neurons has been shown to induce antidepressant-like
phenotypes in mice, probably resulting from changes in
NMDA receptor subunit composition [120].
Chromatin remodeling by post-translational modifica-
tions of histones is also critical for the induction and stabi-
lization of long-term memory. For example, contextual fear
conditioning in adult mice upregulates H3K4 methylation, a
mark of active transcription, in the hippocampus, at specific
promoter regions of Zif268 and Bdnf genes. Mice deficient
for the H3K4 HMT MLL displayed deficits in fear memory
formation, demonstrating that histone methylation is active-
ly regulated in the hippocampus and facilitates long-term
memory formation [121]. H3K4 methylation is also in-
creased at the promoters of GABAergic genes such as
Gad1 during human and rodent cerebral cortex maturation
[122]. Consistent with this, mice expressing one allele of a
truncated Mll transgene showed decreased H3K4



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































methylation levels at GABAergic gene promoters [122].
Because the brains of schizophrenic patients exhibit de-
creased levels of H3K4me3 at the Gad1 promoter and
decreased GAD1 expression, this mechanism may be im-
portant for the pathophysiology of schizophrenia [122].
Finally, some studies in mice showed an involvement of
H3K9 methylation in drug-induced neuronal gene transcrip-
tion changes that may regulate structural and behavioral
plasticity. Indeed, chronic cocaine administration induces
the reduction of H3K9me2 and G9a HMT expression in
nucleus accumbens neurons, associated with increased den-
dritic spine plasticity and enhanced cocaine preference,
suggesting a role of histone methylation in the molecular
mechanisms of drug addiction [123]. Consistent with these
findings, repeated cocaine treatment in mice or ablation of
the H3K9 HMT G9a in the nucleus accumbens increased
mouse susceptibility to social stress, and overexpression of
G9a in the nucleus accumbens rendered mice resilient to
stress even after repeated cocaine treatment [124]. A recent
study also reports a decrease of H3K9 trimethylation at the
Bdnf promoters II and III after long-term morphine absti-
nence in the rat brain [138].
Conclusion and Perspectives
Histone methylation is a major chromatin-remodeling pro-
cess that regulates transcriptional activity. Depending on the
exact location of the methyl group transferred by the HMT,
this modification can either lead to transcriptional activation
or repression. In addition, the combination of histone meth-
ylation with other histone modifications allows the fine-
tuning of transcriptional activity. Consistently, HMTs and
HDMs are often found in multiprotein complexes contain-
ing other histone modification enzymes such as HATs and
HDACs. In particular, the coordinated action of HDACs
with HMTs appears as a very frequent event.
Because of its key function in the regulation of transcrip-
tional activity, histone methylation has become a very active
area of current investigation, in particular in cancer research,
but also more recently in neurobiology. Our knowledge on
the functions of histone methylation in the biology of the
nervous system is still very sparse; however, it seems clear
that in-depth understanding of these functions will lead to
major discoveries and advances in medicine. Histone meth-
ylation has critical functions in the development of the
nervous system. Detection of a wide range of aberrant
histone methylations and other histone modifications in
diseases of the nervous system (also reviewed in [139])
suggests that chromatin remodeling also plays an important
role in these pathologies. However, whether these histone
modifications are a cause or a consequence of these diseases
is not yet proven, and a lot more work is needed to elucidate
the underlying mechanisms of these aberrant histone mod-
ifications. From what we currently know, it seems clear that
the consideration of combinations of several histone mod-
ifications rather than single ones will be a requirement for
the success of future therapeutic strategies. There is there-
fore an enormous need to concentrate our efforts in the
integration of coordinated chromatin remodeling mecha-
nisms in our experimental approaches.
Because of their potential involvement in diseases of the
nervous system, HMTs and HDMs could constitute innova-
tive therapeutic targets. Several HMT and HDM inhibitors
already exist and have shown very promising results, espe-
cially in cancer therapy (reviewed in [140]). In addition, the
identification of new compounds that specifically target
HMTs and HDMs is a very active area of current investiga-
tion. We can thus envision the exciting perspective that
novel research tools will be soon available to elucidate the
functions of histone methylation in neurobiology and that
novel compounds may be useful for the treatment of neuro-
logical diseases.
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